SAN CARLOS, Calif., May 15, 2020 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported financial results and business highlights for the first quarter of 2020 and filed its quarterly report on Form 10-Q for the three months ended March […]
Financial
Surmodics Names Gordon Weber as Senior Vice President of Legal, General Counsel and Secretary
EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced today Gordon Weber has joined Surmodics as Senior Vice President of Legal, General Counsel and Secretary effective May 13, 2020. “Gordon is a seasoned executive with over […]
Milestone Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Clinical and Corporate Update
MONTREAL and CHARLOTTE, N.C., May 14, 2020 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the first quarter ended March 31, 2020 and provided a clinical and corporate update. “While the NODE-301 trial of etripamil for patients with paroxysmal supraventricular […]
Acarix AB (publ) publishes Interim Report, January – March 2020
Press release (MAR) Malmö, May 14, 2020 Acarix AB (publ) publishes Interim Report, January – March 2020 Continued focus on strategic key priorities During the quarter we have kept focus on our priorities along with managing the impact from the global Covid-19 situation. We have been in continued dialogue with […]
Shockwave Medical Reports First Quarter 2020 Financial Results
SANTA CLARA, Calif., May 12, 2020 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended March 31, 2020. Recent Highlights Recognized revenue of $15.2 million […]
Cereno Scientific Expands Footprint Into the United States With a Subsidiary in Boston, MA
STOCKHOLM, May 13, 2020 /PRNewswire/ — Cereno Scientific today announced that the company has expanded its global footprint by establishing a subsidiary with new office space located in Kendall Square at the Cambridge Innovation Center (CIC), Cambridge, Boston, Massachusetts. The CIC is one of the industry’s most recognized biotechnology hubs and has supported more than […]
Medicure Reports Financial Results for Quarter Ended March 31, 2020
WINNIPEG, May 12, 2020 /PRNewswire/ – Medicure Inc. (“Medicure” or the “Company“) (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, today reported its results from operations for the quarter ended March 31, 2020. Quarter Ended March 31, 2020 Highlights: Recorded total net revenue from the sale of products of $3.0 million during the quarter ended March 31, 2020 compared to $4.9 million for […]
CARMAT Obtains Approval for the Reimbursement of Its Total Artificial Heart During the US Clinical Feasibility Study
Centers for Medicare & Medicaid Services (CMS) confirms coverage of the device and routine care items and services PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (Paris:ALCAR) (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart […]
PhaseBio Reports First Quarter 2020 Financial Results and Recent Business Highlights
Initiated PB2452 Phase 3 Trial for the Reversal of the Antiplatelet Effects of Ticagrelor MALVERN, Pa & SAN DIEGO–(BUSINESS WIRE)–PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today reported financial results from the first quarter ending March 31, […]
MyoKardia Announces Primary and All Secondary Endpoints Met in Phase 3 EXPLORER Clinical Trial of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
Highly Statistically Significant Improvements in NYHA Classification, Peak VO2, and LVOT Gradient Observed vs. Placebo Mavacamten Well Tolerated; Safety Results Comparable to Placebo U.S. Regulatory Submission Planned for Early 2021 MyoKardia to Host Conference Call at 8:00 a.m. ET BRISBANE, Calif., May 11, 2020 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK) […]



